significant difference between maribavir and a placebo in reducing the rate of CMV disease. Failed products Oral pleconaril was ViroPharma's first compound, licensed from Sanofi in 1995. Pleconaril is active against viruses in the picornavirus family. ViroPharma's first indication was for enteroviral meningitis, but that indication was abandoned when the clinical trials did not demonstrate efficacy. In 2001, ViroPharma submitted a New Drug Application of pleconaril to the FDA for the common cold. On 2002-03-19, the FDA Antiviral Advisory Committee recommended that the company had failed to show adequate safety, and the FDA subsequently issued a not-approvable letter. In November 2004, ViroPharma licensed pleconaril to Schering-Plough, who are developing an intranasal formulation for the common cold and asthma exacerbations. (Schering-Plough Development Pipeline). In August 2006, Schering-Plough started a Phase II clinical trial. References Further references The Long Road Ahead for ViroPharma Motley Fool 29 September 2006 External links viropharma.com Companies formerly listed on the Nasdaq Pharmaceutical companies established in 1994 Biotechnology companies established in 1994 Biotechnology companies of the United States Defunct pharmaceutical companies of the United States Health care companies based in Pennsylvania Defunct companies based in Pennsylvania Companies based in Chester County, Pennsylvania Orphan drug companies Life sciences industry American companies established in 1994 1994 establishments in Pennsylvania Pharmaceutical companies disestablished in 2014 2014 disestablishments in Pennsylvania 2014 mergers and acquisitions